Quince Therapeutics, Inc. (QNCX) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
QNCX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
QNCX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export QNCX earnings history in CSV or JSON format
Free sign-in required to download data
Quince Therapeutics, Inc. (QNCX) Earnings Overview
As of May 8, 2026, Quince Therapeutics, Inc. (QNCX) reported trailing twelve-month net income of -$84M, reflecting -28.2% year-over-year growth. The company earned $-16.76 per diluted share over the past four quarters.
Looking at the long-term picture, QNCX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12M in fiscal 2017.
Quince Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACAD ($376M net income, 36.5% margin), QNCX has comparable earnings metrics. Compare QNCX vs RARE →
QNCX Earnings vs Peers
Earnings metrics vs comparable public companies
QNCX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$84M | -47.8% | -$50M | $-16.80 | - | - |
| 2024 | -$57M | -81.1% | -$57M | $-13.10 | - | - |
| 2023 | -$31M | +39.2% | -$35M | $-8.40 | - | - |
| 2022 | -$52M | +42.6% | -$52M | $-15.40 | - | - |
| 2021 | -$90M | -17.0% | -$90M | $-30.30 | - | - |
| 2020 | -$77M | -107.8% | -$79M | $-26.30 | - | - |
| 2019 | -$37M | -196.4% | -$39M | $-19.30 | - | - |
| 2018 | -$12M | -2.0% | -$12M | $-5.80 | - | - |
| 2017 | -$12M | - | -$10M | $-5.70 | - | - |
See QNCX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QNCX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QNCX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonQNCX — Frequently Asked Questions
Quick answers to the most common questions about buying QNCX stock.
Is QNCX growing earnings?
QNCX EPS fell to $-16.76, with earnings declining -28.2%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-84M.
What are QNCX's profit margins?
Quince Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are QNCX's earnings?
QNCX earnings data spans 2017-2025. The declining earnings trend is -28.2% YoY. Historical data enables comparison across business cycles.